ChondroGene Limited has completed the acquisition of GeneNews Inc. The principal asset of GeneNews is proprietary technology, in which ChondroGene presently holds certain licensing rights, in osteoarthritis, rheumatoid arthritis and traumatic joint injury. This technology can be applied to pharmacogenomics and personalized medicine, and in the development of novel diagnostics and therapeutics across a range Read more about Chondrogene Acquires Genenews[…]